$129.00
Manufacturer: USA
Arimidex (anastrozole) is a potent and highly selective nonsteroidal aromatase inhibitor. In postmenopausal women, estradiol is mainly produced by the conversion of androstenedione into estrone in peripheral tissues by the aromatase enzyme complex. Estrone is further converted to estradiol. Lowering circulating estradiol has a therapeutic effect in women with breast cancer. In postmenopausal women, taking Arimidex in a daily dose of 1 mg led to a decrease in estradiol levels by 80%, which was confirmed by a highly sensitive analytical test.
Arimidex (anastrozole) has no progestogenic, androgenic or estrogenic activity.
Description
Ingredients:
active substance: anastrozole;
1 film-coated tablet contains 1 mg of anastrozole;
excipients: lactose, monohydrate; povidone, sodium starch glycolate (type A), magnesium stearate; film shell: hypromellose, macrogol 300, titanium dioxide (E 171).
Medicinal form. Film-coated tablets.
The main physical and chemical properties : round, white, biconvex tablets covered with a film shell. The tablets are engraved.
Pharmacotherapeutic group. Hormone antagonists and related drugs. Aromatase inhibitors. ATX code. L02B G03.
Pharmacological properties.
Pharmacodynamics
Mechanism of action and pharmacodynamic effects
Arimidex (anastrozole) is a potent and highly selective nonsteroidal aromatase inhibitor. In postmenopausal women, estradiol is mainly produced by the conversion of androstenedione into estrone in peripheral tissues by the aromatase enzyme complex. Estrone is further converted to estradiol. Lowering circulating estradiol has a therapeutic effect in women with breast cancer. In postmenopausal women, taking Arimidex in a daily dose of 1 mg led to a decrease in estradiol levels by 80%, which was confirmed by a highly sensitive analytical test.
Arimidex (anastrozole) has no progestogenic, androgenic or estrogenic activity.
Arimidex (anastrozole) in daily doses up to 10 mg does not affect the secretion of cortisol and aldosterone, which was measured before and after a standard test for stimulation of adrenocorticotropic hormone (ACTH). Therefore, there is no need for corticosteroid replacement.
Indication.
Arimidex (anastrozole) is indicated for:
– adjuvant treatment of invasive breast cancer with positive indicators of hormone receptors in the early stages in postmenopausal women;
– adjuvant treatment of invasive breast cancer with positive indicators of hormone receptors in the early stages in postmenopausal women who received adjuvant therapy with tamoxifen for 2-3 years;
– treatment of advanced breast cancer with positive indicators of hormone receptors in postmenopausal women.
Contraindication.
Arimidex (anastrozole) is contraindicated for patients:
– during pregnancy and breastfeeding;
– with known hypersensitivity to anastrozole or any of the excipients.
Dosage and Administration
Arimidex (anastrozole) is taken orally.
The recommended dose for adults, including elderly women, is 1 tablet (1 mg) once a day.
In case of invasive breast cancer with positive indicators of hormone receptors in the early stages in postmenopausal women, the recommended duration of adjuvant endocrine treatment is 5 years.
Impaired kidney function
Patients with mild or moderate renal impairment do not need to adjust the dose. The use of Arimidex in patients with severe renal impairment requires caution.
Violation of liver function
Patients with mild liver disease do not need to adjust the dose. The drug should be used with caution in patients with moderate and severe impairment of liver function.
Recent Reviews